摘要:
The present invention discloses and claims pharmaceutical compositions comprising Group A streptogramin derivatives of formula (I) and salts thereof in combination with at least one natural group B streptogramin derivative.
摘要:
Group A streptogramin derivatives of formula (I) and salts thereof: and Group A streptogramin derivatives of formula (III) and salts thereof: as well as processes for preparing such streptogramins, and pharmaceutical compositions comprising such streptogramins, alone or combined with at least one group B streptogramin derivative.
摘要:
Group A streptogramin derivatives of general formula (I) in which: R1 represents a halogen atom or an azido or thiocyanato radical, R2 represents a hydrogen atom or a methyl or ethyl radical, R3 represents a hydrogen atom, or the residue of an aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic or heterocyclylaliphatic ester which may be substituted, and the bond - - - represents a single bond (stereochemistry 27R) or a double bond, as well as its salts when they exist.
摘要:
The invention relates to the novel materials of formula (I), where: R1 is an optionally substituted L-aryl or L-heteroaryl, such that L is a single bond, alkyl, CO, or CO-alk, or L-X, with L□ being an alkyl and X being O or S; R2 is H or alkyl; R3 is an alkyl optionally substituted by Hal; and R4 is Hou Hal, wherein said materials are in any isomeric form and the salts thereof, to be used as drugs.
摘要:
The invention relates to novel products of formula (Ia) or (Ib): these products being in all the isomeric forms and salts as drugs, notably as anticancer drugs.
摘要:
The invention relates to the novel materials of formula (I), where R1 is an optionally substituted L-aryl or -heteroaryl, such that L is: an alkyl or CO, or LX, with Lbeing an alkyl and X being O or S; R2 is H or an alkyl; R3 is an alkyl optionally substituted by Hal; and R4 is Hou Hal, wherein said materials are in any isomeric form and the salts thereof, to be used as drugs.
摘要:
The invention relates to a product of formula (I) where R1, R2, R3, and R4 are as defined herein, the therapeutic use of the product, a process to make the product, and a pharmaceutical composition comprising the product.
摘要:
The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity.What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or de-myelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.
摘要:
The invention relates to novel products of formula (Ia) or (Ib): these products being in all the isomeric forms and salts as drugs, notably as anticancer drugs.
摘要:
The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing peroxisome proliferator activator receptor (PPAR) delta agonist activity comprising compounds of formula I, in which the R1-R7 substituents as well as the U, V, W, X Y and z radicals are as defined herein, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.